drugset
drugset / Trial / NCT04867642

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

NCT04867642 ↗

Phase 1 Completed 100 enrolled UCB Biopharma SRL
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of UCB0022 and food effect.

Timeline

Start
2021-04-29
Primary completion
2023-02-27
Completion
2023-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject glovadalen Small molecule — —

Indications

Parkinson disease